MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3372 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China

NCT04573283

Metabolic Associated Fatty Liver Disease

RECRUITING

Clinical Characteristics of Metabolic Associated Fatty Liver Disease

NCT06325254

Metabolic Associated Fatty Liver Disease Clinical Features

RECRUITING

Association Betweenq MAFLD ( Metabolic Associated Fatty Liver Disease) and Chronic Kidney Disease

NCT06135467

Mafld in Ckd Patients

NOT_YET_RECRUITING

The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods

NCT06061640

Metabolic Dysfunction-associated Fatty Liver Disease

UNKNOWN

Lifestyle Modification for MAFLD Based on TTM

NCT04871880

Metabolic Associated Fatty Liver Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases. It affects nearly 25% of the global population. Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries. It may provide a better understanding of MAFLD, and optimize strategies for prevention of extrahepatic complications in clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Associated Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

participants were followed for the incidence of T2DM in a cohort study

performed a cohort analysis for T2DM. For incident T2DM cases, calculate the follow-up time from the date of enrollment into our study to the date of T2DM diagnosis.

the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Intervention Type DIAGNOSTIC_TEST

participants were followed for the incidence of hypertension in a cohort study

performed a cohort analysis for hypertension. For incident hypertension cases, calculate the follow-up time from the date of enrollment into our study to the date of hypertension diagnosis.

the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Intervention Type DIAGNOSTIC_TEST

participants were followed for the incidence of carotid atherosclerotic plaque in a cohort study

performed a cohort analysis for carotid atherosclerotic plaque. For incident carotid atherosclerotic plaque cases, calculate the follow-up time from the date of enrollment into our study to the date of carotid atherosclerotic plaque diagnosis.